Exonbio has developed an extensive portfolio of antibodies against SARS-CoV-2 Spike and Nucleocapsid proteins. The virus attaches to the cell that through an interaction between the spike protein on the surface of the viral particle and a receptor protein, ACE2 on the surface of the cell. The antibodies bind to the spike protein and prevent it from interacting with ACE2 receptor on the host cell, neutralizing the virus making it unable to infect the cells. The nucleocapsid protein is highly immunogenic phosphoprotein. It is also involved in CoV replication cycle and the host cellular response to viral infection.
Exonbio has developed hundreds of clones of rabbit monoclonal antibodies using proprietary SPIN® technology. SARS-CoV-2 Reagent Antigens